Acrivon Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ACRV Nasdaq 2834 acrivon.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Acrivon Therapeutics, Inc.

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - Jan 8th, 2026 5:30 am
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? - Jan 7th, 2026 7:40 am
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast - Jan 6th, 2026 5:30 am
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast - Dec 17th, 2025 7:34 am
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates - Dec 17th, 2025 5:30 am
3 Promising Penny Stocks With Market Caps Over $70M - Dec 11th, 2025 5:05 am
H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT - Nov 28th, 2025 11:26 pm
Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights - Nov 13th, 2025 2:10 pm
3 Promising Penny Stocks With Market Caps Over $20M - Nov 4th, 2025 11:05 am
Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks - Nov 2nd, 2025 3:05 am
Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference - Oct 22nd, 2025 2:15 pm
Spotlight On 3 Promising Penny Stocks With Over $50M Market Cap - Oct 2nd, 2025 12:05 pm
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Oct 1st, 2025 2:30 pm
Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - Aug 13th, 2025 2:15 pm
Here's Why We're Watching Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation - Jul 22nd, 2025 8:12 am
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch - May 17th, 2025 10:30 am
Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - May 14th, 2025 2:10 pm
Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now - May 5th, 2025 7:55 am
Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 - Apr 25th, 2025 6:00 am
April 2025's Standout Penny Stocks - Apr 22nd, 2025 12:05 pm